Chemical Approaches for Developing Potent Kinase Inhibitors and DNA-Targeting Agents in Cancer Therapy

Protein kinases are essential regulators of cell signaling and DNA integrity, playing a pivotal role in cancer initiation and progression. Targeted small-molecule therapies, particularly kinase inhibitors, have revolutionized cancer treatment by disrupting key signaling pathways involved in cell cycle control and tumor growth. This book chapter covers the structural diversity and mechanisms of protein kinase inhibitors, including their classification and examples such as imatinib, erlotinib, and sorafenib. Furthermore, advances in DNA-targeting agents, such as alkylating compounds and topoisomerase inhibitors, complement existing kinase-directed strategies. Recent innovations focus on dual-targeting molecules that combine kinase inhibition with DNA interaction, offering enhanced efficacy and overcoming resistance mechanisms. Chemical strategies, such as structure-based drug design, fragment-based approaches, and covalent or allosteric inhibitors, are discussed alongside the challenge of resistance and ongoing solutions through combination therapies. Case studies of FDA-approved drugs and novel candidates underscore emerging trends and future perspectives in the rational development of anticancer agents that target both kinases and DNA.